Bioinnovation Leader Novozymes Selects PROS Pricing Software to Support Profit Initiative
Danish Firm Looks to PROS to Help Implement New Pricing Strategies
June 21, 2011
HOUSTON – PROS (NYSE: PRO), the world leader in pricing and revenue management software, today announced that Novozymes, a leading bioinnovation company based in Denmark, selected PROS software as a key enabler to implement a profit improvement initiative as it expands its global footprint.
With $1.8 billion in annual revenue, Novozymes is an international leader in the development, production, distribution and sale of enzymes used in a variety of industries from agriculture to consumer products. Novozymes offers bioinnovative products, including industrial enzymes, beneficial microorganisms, biopolymers and other proteins.
"After a thorough evaluation of pricing software vendors, Novozymes selected PROS as the optimum solution and partner to support our growth and profit improvement initiatives,” said Novozymes Chief Marketing Officer Henrik Meyer, who also leads the company’s strategic pricing strategies. “The PROS low-risk implementation approach, its focus on delivering value quickly, and its endorsements by high-credibility customers and industry thought leaders, gave us confidence that they were the right choice for a long-term partnership. Through this strategic implementation, our sales teams will be empowered to be successful with far better transparency and guidance as they work in partnership with our customers.”
Novozymes is leveraging all three advanced pricing modules incorporated in the PROS Pricing Solution Suite, including Scientific Analytics™, Price Optimizer™ and Deal Optimizer™. The three modules seamlessly work together to support the entire pricing lifecycle, from identifying pricing opportunities, to setting pricing strategies and executing optimized prices. With PROS, customers are able to improve revenue and profitability, defend and grow market share, and improve business agility.
“Novozymes is recognized worldwide for its innovative technologies and commitment to more sustainable and eco-efficient solutions, and we’re honored to have been selected to help drive their profitable growth efforts,” said PROS Europe General Manager Wagner Williams. “Like PROS, Novozymes makes substantial investments in research and development as the engine to help propel growth.”
“One of the biggest challenges for innovative companies is making timely pricing decisions in a climate of rapid growth and increasing global competition,” said PROS President and CEO Andres Reiner. “The power of prescriptive pricing provides organizations with a strategic enabler to increase profitability as stakeholders look to companies for greater accountability in their business operations. As a global biotechnology leader, Novozymes is setting a new course for its business operations by embarking on its pricing journey.”
Novozymes is a bioinnovation company based in Denmark, producing industrial enzymes, microorganisms, and biopharmaceutical ingredients for a variety of businesses. Novozymes employs more than 5,000 people developing products for industries that include bioenergy, agriculture, household products, textiles, and food and beverages. Novozymes biological solutions help companies make more from less with solutions that save energy and raw materials, and reduce waste. The result is higher quality, lower costs, lower CO2 emissions and a better environment.
PROS Holdings, Inc. (NYSE: PRO) is a big data software company that helps customers outperform in their markets by using big data to sell more effectively. We apply 27 years of data science experience to unlock buying patterns and preferences within transaction data to reveal which opportunities are most likely to close, which offers are most likely to sell and which prices are most likely to win. PROS offers big data solutions to optimize sales, pricing, quoting, rebates and revenue management across more than 30 industries. PROS has implemented more than 600 solutions in more than 55 countries. The PROS team comprises more than 700 people around the world. To learn more, visit www.pros.com.
This press release contains forward-looking statements, including statements about the functionality and benefits of pricing software to organizations generally as well as the functionality and benefits of PROS software products. The forward-looking statements contained in this press release are based upon PROS historical experience with pricing and big data software and its current expectations of the benefits of pricing and big data software for organizations that implement and utilize such software. Factors that could cause actual results to differ materially from those described herein include the addressability of an organization’s pricing and revenue management needs, the risks associated with PROS developing and enhancing products with the functionality necessary to deliver the stated results and the risks associated with the complex implementation and maintenance of pricing and big data software such as PROS software products. Additional information relating to the uncertainty affecting the PROS business is contained in PROS filings with the Securities and Exchange Commission. These forward-looking statements represent PROS expectations as of the date of this press release. Subsequent events may cause these expectations to change, and PROS disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise.
# # #